James Maitland brings a wealth of clinical perspective to the intersection of artificial intelligence and cardiovascular medicine. As an expert in robotics and medical IoT applications, he has spent his career exploring how high-fidelity data can transform the way we diagnose chronic conditions before they become acute emergencies. In this discussion, we explore the recent FDA authorization of a tool that seeks to identify the “hidden” drivers of heart attacks—specifically coronary inflammation—which often remains invisible during routine clinical evaluations. This technological shift represents a move away from simply viewing the heart as a series of pipes to be unblocked and toward understanding it as a complex biological system where inflammation dictates future outcomes.
Traditional scans often focus on physical blockages, yet many patients with clear arteries still suffer from sudden cardiac events; how does this new technology specifically address that diagnostic gap?
This technology fills a massive void in preventative cardiology by looking at the biological activity within the vessel wall rather than just the physical space inside the artery. Traditional coronary computed tomography angiography is excellent at finding narrowed or blocked vessels, but it often misses the inflammatory markers that lead to plaque rupture. The CaRi-Heart tool uses AI to quantify this coronary inflammation from routine scans, allowing us to estimate a patient’s risk of cardiovascular mortality over a ten-year period. By assigning patients to low, medium, or high-risk categories, we can finally identify individuals who would have otherwise been sent home with a clean bill of health despite being at high risk for a major event. It essentially gives us a way to see the “smoke” before there is a “fire” in the coronary arteries.
The recent research conducted across several hospitals in the U.K. showed some startling figures regarding patient outcomes; could you explain the significance of those findings for clinical practice?
The scale of that study was truly impressive, involving more than 40,000 people across eight U.K. hospitals who were tracked for a median of 2.7 years. What we found was that patients without obstructive coronary artery disease actually accounted for two-thirds of all major adverse cardiac events and total cardiac deaths. This statistic is a wake-up call for the medical community because it proves that our current focus on physical blockages is only capturing a small fraction of the total risk. By using AI to differentiate very high-risk patients from those at low or medium risk, we can tailor intensive preventative treatments to those who need them most. This evidence-based approach ensures that the two-thirds of patients who were previously invisible to our diagnostic tools now have a chance at early intervention.
From a technical standpoint, how does the AI integrate diverse biological markers like plaque burden and radiological changes to create a reliable risk profile?
The AI functions by performing a deep-tissue analysis of the radiological changes that are induced by inflammation, which are often too subtle for the human eye to detect on a standard scan. It then synthesizes this data with the patient’s total plaque burden and other specific clinical risk factors to produce a unified risk score. This is a significant step up from the CaRi-Plaque technology cleared last year, as it adds the dynamic layer of inflammation to the static measurement of stenosis. By quantifying these multi-dimensional markers, the system provides a holistic view of the heart’s health that is grounded in hard data rather than just visual estimation. This level of precision allows for a much more accurate stratification of patients, particularly those who present with chest pain but show no obvious signs of narrowing in their vessels.
Now that the commercial launch is beginning in the United States, what do you see as the primary drivers for its adoption across American healthcare systems?
The most significant driver is the recent implementation of specific reimbursement codes that took effect in January, which provides a clear financial pathway for hospitals to adopt this technology. In addition to that, the company has assembled a very strong leadership team with experience from high-stakes medical firms like OrganOx, which recently sold for $1.5 billion. We are expecting a commercial launch this quarter with a much broader rollout planned for the fourth quarter of the year. This aggressive timeline is supported by the fact that the tool is the first of its kind to be authorized in the U.S. for quantifying coronary inflammation from routine imaging. As more facilities realize they can gain these insights without changing their standard imaging hardware, the adoption rate is likely to climb rapidly.
What is your forecast for the role of AI in cardiac diagnostics over the next decade?
I believe that within the next ten years, we will see a complete shift where no cardiac scan is considered complete without an integrated AI analysis of inflammatory and metabolic markers. We are moving toward a future where “sudden” heart attacks are no longer a surprise because we will have identified the inflammatory precursors a decade in advance. As these tools become more autonomous and integrated into the standard workflow, they will likely be used to monitor the effectiveness of anti-inflammatory medications in real-time. This will eventually lead to a personalized medicine model where every patient has a dynamic risk score that is updated with every routine scan. Ultimately, the integration of AI will bridge the gap between high-level imaging and daily clinical decision-making, saving millions of lives by focusing on prevention over reaction.
